Autopsy report · NCT06326138

Pharmacokinetics and Pharmacodynamics of Edoxaban Before and After Bariatric Surgery

“No support form the sponsor”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

Institut universitaire de cardiologie et de pneumologie de Québec, University Laval

Sponsor type

University, hospital or other

Conditions

Bariatric Surgery Candidate

Interventions

Edoxaban Pharmacokinetics and Pharmacodynamics

Participants

0

Trials that died the same way

• 18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma
  “loss of sponsor support” (80% match in meaning)
• Immunotherapy for Advanced Liver Cancer
  “Sponsor unable to fund” (77% match in meaning)
• Natalizumab and Chronic Inflammation
  “Sponsor declined further support” (76% match in meaning)
• The Effect of Theraworx Foam in Carpal Tunnel Syndrome
  “Lack of Funding from Sponsor” (76% match in meaning)
• Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma
  “Sponsor withdrew support” (75% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.